Kyowa Kirin initiates first-in-human trial for KK2223 in T Cell Non-Hodgkin Lymphoma
Kyowa Kirin is conducting a first-in-human study to evaluate KK2223 in patients with relapsed or refractory T cell lymphoma.
Therapeutic Area
Therapeutic area intelligence for T Cell Non-Hodgkin Lymphoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.